NOVC.DE实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (14 Nov 2023 @ 23:35):

Stats
今日成交量	26 806.00
平均成交量	51 037.00
市值	406.69B
EPS	€8.63 ( 2023-06-30 )
Last Dividend	€3.00 ( 2023-08-18 )
Next Dividend	€0 ( N/A )
P/E	22.91
ATR14	€2.62 (2.86%)

音量相关性

長: 0.32 (neutral)

短: -0.73 (moderate negative)

Signal:(48.651) Neutral

Novo Nordisk A/S 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Novo Nordisk A/S 相关性 - 货币/商品

-0.84
( strong negative )

-0.91
( very strong negative )

0.39
( neutral )

-0.86
( strong negative )

-0.01
( neutral )

0.88
( strong )

Novo Nordisk A/S 财务报表

Annual	2022
营收:	€176.95B
毛利润:	€148.51B (83.92 %)
EPS:	€24.51

FY	2022
营收:	€176.95B
毛利润:	€148.51B (83.92 %)
EPS:	€24.51

FY	2021
营收:	€140.80B
毛利润:	€117.14B (83.20 %)
EPS:	€20.79

FY	2020
营收:	€126.95B
毛利润:	€106.01B (83.51 %)
EPS:	€18.05

Financial Reports:

No articles found.

Novo Nordisk A/S Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
€4.25 (N/A)	€0 (N/A)	€8.15 (N/A)	€0 (N/A)	€3.00 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)

Novo Nordisk A/S Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 6.14 - average (71.63%) | Divividend Growth Potential Score: 4.38 - Stable (12.49%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	€0.670	2002-03-13
Last Dividend	€3.00	2023-08-18
Next Dividend	€0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	30	--
Total Paid Out	€100.58	--
Avg. Dividend % Per Year	0.00%	--
Score	2.88	--
Div. Sustainability Score	6.14
Div.Growth Potential Score	4.38
Div. Directional Score	5.26	--

Next Divdend (Est)
(2024-04-29)

€2.78 Estimate 6.71 %

Dividend Stability

0.27 Very Poor

Dividend Score

2.88

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for XETRA

Symbol	Title	Last dividend	Frequency	Yearly Dividend
SNW.DE	Ex Dividend Knight	2023-05-30	Annually	0.00%
CPIA.F	No Dividend Player	2023-06-29	Annually	0.00%
LHOG.F	Ex Dividend Junior	2023-08-24	Semi-Annually	0.00%
185.DE	Ex Dividend Junior	2023-08-07	Quarterly	0.00%
UTDI.DE	Ex Dividend Junior	2023-05-18	Annually	0.00%
ED4.DE	Ex Dividend Junior	2023-06-29	Sporadic	0.00%
NOA3.DE	Ex Dividend Knight	2023-10-23	Semi-Annually	0.00%
ADN1.DE	Ex Dividend Junior	2023-06-02	Annually	0.00%
ZOE.DE	Ex Dividend Knight	2023-07-20	Quarterly	0.00%
GIL.DE	Ex Dividend Junior	2023-05-15	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.351	1.500	2.98	4.47	[0 - 0.5]
returnOnAssetsTTM	0.251	1.200	1.635	1.962	[0 - 0.3]
returnOnEquityTTM	0.869	1.500	1.460	2.19	[0.1 - 1]
payoutRatioTTM	0.422	-1.000	5.78	-5.78	[0 - 1]
currentRatioTTM	0.824	0.800	-0.880	-0.704	[1 - 3]
quickRatioTTM	0.635	0.800	-0.971	-0.777	[0.8 - 2.5]
cashRatioTTM	0.175	1.500	-0.141	-0.211	[0.2 - 2]
debtRatioTTM	0.0884	-1.500	8.53	-10.00	[0 - 0.6]
interestCoverageTTM	-18.83	1.000	-8.08	-8.08	[3 - 30]
operatingCashFlowPerShareTTM	23.78	2.00	2.07	4.15	[0 - 30]
freeCashFlowPerShareTTM	17.38	2.00	1.308	2.62	[0 - 20]
debtEquityRatioTTM	0.285	-1.500	8.86	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.841	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	0.392	1.000	4.16	4.16	[0.1 - 0.6]
cashFlowToDebtRatioTTM	4.01	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.715	0.800	8.57	6.85	[0.5 - 2]
Total Score				6.14

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	40.52	1.000	6.01	0	[1 - 100]
returnOnEquityTTM	0.869	2.50	4.51	2.19	[0.1 - 1.5]
freeCashFlowPerShareTTM	17.38	2.00	4.21	2.62	[0 - 30]
dividendYielPercentageTTM	0.440	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	23.78	2.00	2.07	4.15	[0 - 30]
payoutRatioTTM	0.422	1.500	5.78	-5.78	[0 - 1]
pegRatioTTM	0.142	1.500	-2.38	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.496	1.000	0.0917	0	[0.1 - 0.5]
Total Score				4.38

Novo Nordisk A/S

Novo Nordisk A/S is a healthcare company, which engages in the research, development, manufacture, and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.